KEYNOTE-006 中帕博利珠单抗对比伊匹木单抗治疗晚期黑色素瘤的患者报告结局
KEYNOTE-006 是一项随机 III 期研究,比较帕博利珠单抗与伊匹木单抗在伊匹木单抗初治晚期黑色素瘤患者中的患者报告健康相关生活质量(HRQoL)和症状。主要 PRO 分析为第 12 周 EORTC QLQ-C30 总体健康状况(GHS)/HRQoL 评分较基线的变化。结果显示帕博利珠单抗组 HRQoL 维持优于伊匹木单抗组。
要点
- 第 12 周 GHS/HRQoL 评分变化:帕博利珠单抗 Q2W 组 -1.9、Q3W 组 -2.5,伊匹木单抗组 -10.0,各帕博利珠单抗组对比伊匹木单抗组 p<0.001。
- 第 12 周 GHS 恶化患者比例:帕博利珠单抗 Q2W 组 31%、Q3W 组 29%,伊匹木单抗组 44%。
- PRO 分析人群共 776 例:帕博利珠单抗 Q2W 组 n=270、Q3W 组 n=266、伊匹木单抗组 n=240。
核心结论
- 在伊匹木单抗初治晚期黑色素瘤患者中,帕博利珠单抗组 HRQoL 维持优于伊匹木单抗组。
研究设计与样本
- III 期 KEYNOTE-006 研究,患者接受帕博利珠单抗 10 mg/kg 每 2 周(Q2W)或每 3 周(Q3W)最长 2 年,或伊匹木单抗 3 mg/kg Q3W 共 4 周期。
- PRO 分析为预设探索性终点,主要 PRO 评估为第 12 周 EORTC QLQ-C30 总体健康状况(GHS)/HRQoL 评分较基线变化,采用约束纵向数据分析。
- PRO 分析人群共 776 例:帕博利珠单抗 Q2W 组 n=270、Q3W 组 n=266、伊匹木单抗组 n=240。
主要发现
- 基线 GHS 在各组间相似。
- 第 12 周 QLQ-C30 依从率:帕博利珠单抗 Q2W 组 87%(n=214)、Q3W 组 97%(n=226)、伊匹木单抗组 96%(n=178)。
- 基线至第 12 周 GHS/HRQoL 评分变化:帕博利珠单抗 Q2W 组 -1.9、Q3W 组 -2.5,伊匹木单抗组 -10.0;各帕博利珠单抗组对比伊匹木单抗组 p<0.001。
- 第 12 周 GHS 恶化患者比例:帕博利珠单抗 Q2W 组 31%、Q3W 组 29%、伊匹木单抗组 44%,个体功能和症状量表呈现相似趋势。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Report results of patient-reported health-related quality of life (HRQoL) and symptoms from phase III KEYNOTE-006 study of pembrolizumab versus ipilimumab in patients with ipilimumab-naive advanced melanoma. PATIENTS AND METHODS: Patients received pembrolizumab 10 mg/kg every 2 (Q2W) or every 3 weeks (Q3W) for up to 2 years, or four cycles of ipilimumab 3 mg/kg Q3W. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) was administered at baseline and throughout the study. Patient-reported outcome (PRO) analyses were pre-specified exploratory endpoints; the primary PRO assessment was the score change from baseline to week 12 in EORTC QLQ-C30 global health status (GHS)/HRQoL score between the arms using constrained longitudinal data analysis. RESULTS: The PRO analysis population included 776 patients: pembrolizumab Q2W (n = 270); pembrolizumab Q3W (n = 266); ipilimumab (n = 240). Baseline GHS was similar across arms. QLQ-C30 compliance rates at week 12 were 87% (n = 214), 97% (n = 226), and 96% (n = 178), for the pembrolizumab Q2W, pembrolizumab Q3W, and ipilimumab arms, respectively. From baseline to week 12, GHS/HRQoL scores were better maintained with pembrolizumab than with ipilimumab (decrease of -1.9 and -2.5 for pembrolizumab versus -10.0 for ipilimumab; p < 0.001 for each pembrolizumab arm versus ipilimumab). Fewer patients treated with pembrolizumab experienced deterioration in GHS at week 12 (31% for pembrolizumab Q2W; 29% for Q3W and 44% for ipilimumab), with similar trends observed for individual functioning and symptoms scales. CONCLUSIONS: HRQoL was better maintained with pembrolizumab than with ipilimumab in patients with ipilimumab-naive advanced melanoma. CLINICALTRIALS. GOV IDENTIFIER: NCT01866319.
引用
- Petrella TM, Robert C, Richtig E, et al. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. Eur J Cancer. 2017. PMID: 28987768. doi:10.1016/j.ejca.2017.08.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。